Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Status and phase: Terminated; Phase 2

Conditions: B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Acute Lymphoblastic Leukemia in Remission

Treatments: Drug: Dexamethasone; Drug: Cyclophosphamide; Biological: Ofatumumab; Drug: Doxorubicin Hydrochloride; Drug: Prednisone; Biological: Inotuzumab Ozogamicin; Biological: Rituximab; Drug: Cytarabine; Drug: Leucovorin Calcium; Drug: Vincristine Sulfate; Drug: Methotrexate; Other: Laboratory Biomarker Analysis; Drug: Mercaptopurine

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT03488225

P30CA016672 (U.S. NIH Grant/Contract)

2015-0922 (Other Identifier)

NCI-2018-00760 (Registry Identifier)

Details and patient eligibility

About

This phase II trial studies how well combination chemotherapy and inotuzumab ozogamicin work in treating patients with B acute lymphoblastic leukemia. Drugs used in chemotherapy, such as cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone, methotrexate and cytarabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as inotuzumab ozogamicin, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy and inotuzumab ozogamicin may work better at treating B acute lymphoblastic leukemia.

Full description

PRIMARY OBJECTIVES:

I. To evaluate the clinical efficacy of the sequential combination of hyper-CVAD (hyperfractionated cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone, methotrexate and cytarabine) + inotuzumab ozogamicin in patients with newly diagnosed B-cell acute lymphocytic leukemia (ALL) in terms of event-free survival (EFS).

SECONDARY OBJECTIVES:

I. To evaluate other efficacy endpoints such as overall survival, overall response rate, minimal residual disease (MRD) negativity rate as well as the safety of this combination.

OUTLINE:

INTENSIVE CHEMOTHERAPY: Patients receive cyclophosphamide intravenously (IV) over 3 hours every 12 hours on days 1-3 and dexamethasone IV or orally (PO) on days 1-4 and 11-14 of courses 1 and 3. Patients may receive ofatumumab IV over 2 hours on days 1, 2 and 11 of course 1, days 1 and 8 of courses 2 and 4, and days 1 and 11 of course 3, or rituximab IV over 2 hours on days 1 and 11 of courses 1 and 3, and days 1 and 8 of courses 2 and 4. Patients also receive methotrexate intrathecally (IT) on day 2 of courses 1 and 3, IV over 24 hours on day 1 and IT on day 8 of courses 2 and 4, doxorubicin hydrochloride IV over 24 hours on day 4 of courses 1 and 3, vincristine sulfate IV over 1 hour on days 4 and 11 of courses 1 and 3, cytarabine IT on day 7 of courses 1 and 3, and IV over 2 hours every 12 hours on days 2 and 3, and IT on day 5 of courses 2 and 4, leucovorin calcium IV 4 times a days on day 2 of courses 2 and 4. Patients then receive inotuzumab ozogamicin IV over 1 hour on days 1 and 8 of courses 5-8. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.

MAINTENANCE THERAPY: Patients receive mercaptopurine PO thrice a day, methotrexate PO once a week, vincristine sulfate IV over 1 hour on day 1 and prednisone PO on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days and every 6 months.

Enrollment: 4 patients

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with newly diagnosed, previously untreated B-lineage ALL, or having achieved complete remission (CR) with one course of induction chemotherapy
• Patients with extramedullary disease only are eligible
• Failure to one induction course of chemotherapy (these patients will be analyzed separately)
• Performance status of 0-3
• Creatinine less than or equal to 2.0 mg/dL (unless considered tumor related)
• Bilirubin less than or equal to 2.0 mg/dL (unless considered tumor related)
• Adequate cardiac function as assessed by history and physical examination
• No active or co-existing malignancy with life expectancy less than 12 months
• Women of childbearing potential (WOCBP) or male subjects with a partner who is WOCBP must agree to use contraception during the study, if sexually active

Exclusion criteria

• Pregnant or nursing women
• Known to be human immunodeficiency virus (HIV)-positive
• Philadelphia chromosome (Ph)-positive ALL
• Active and uncontrolled disease/infection as judged by the treating physician
• Unable or unwilling to sign the consent form
• Subjects who have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver involvement or stable chronic liver disease per investigator assessment)
• Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active hepatitis C

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

4 participants in 1 patient group

Treatment (hyper-CVAD, inotuzumab ozogamicin)

Experimental group

Description:

See detailed description.

Treatment:

Drug: Mercaptopurine

Other: Laboratory Biomarker Analysis

Drug: Methotrexate

Drug: Vincristine Sulfate

Drug: Leucovorin Calcium

Drug: Cytarabine

Biological: Rituximab

Biological: Inotuzumab Ozogamicin

Drug: Prednisone

Biological: Ofatumumab

Drug: Doxorubicin Hydrochloride

Drug: Dexamethasone

Drug: Cyclophosphamide